Chris Shelley

Mr. Chris Shelley

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
JLJianyun Liu
Jianyun Liu
FMFikir M. Mesfin
Fikir M. Mesfin
CHChelsea E. Hunter
Chelsea E. Hunter
Kenneth OlsonKenneth Olson
Kenneth Olson
CSChris Shelley
Chris Shelley
TMTroy A. Markel
Troy A. Markel
Hydrogen sulfide has been recently identified as the third biological gasotransmitter, along with the more well studied nitric oxide (NO) and carbon monoxide (CO). Intensive studies on its potential as a therapeutic agent for cardiovascular, inflammatory, infectious and neuropathological diseases have been undertaken. Here we review the possible direct targets of H2S in mammals. H2S directly interacts with reactive oxygen/nitrogen species and is involved in redox signaling. H2S also reacts with hemeproteins and modulates metal-containing complexes. Once being oxidized, H2S can persulfidate proteins by adding -SSH to the amino acid cysteine. These direct modifications by H2S have significant impact on cell structure and many cellular functions, such as tight junctions, autophagy, apoptosis, vesicle trafficking, cell signaling, epigenetics and inflammasomes. Therefore, we conclude that H2S is involved in many important cellular and physiological processes. Compounds that donate H2S to biological systems can be developed as therapeutics for different diseases.

1 November 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
Sergio Li CalziSergio Li Calzi
Sergio Li Calzi
LSLynn C. Shaw
Lynn C. Shaw
LMLeni Moldovan
Leni Moldovan
CSChris Shelley
Chris Shelley
XQXiaoping Qi
Xiaoping Qi
MGMaria B. Grant
Maria B. Grant
Retinopathy of prematurity (ROP) is a disorder of the developing retina of preterm infants. ROP can lead to blindness because of abnormal angiogenesis that is the result of suspended vascular development and vaso-obliteration leading to severe retinal stress and hypoxia. We tested the hypothesis that the use of the human progenitor cell combination, bone marrow–derived CD34 + cells and vascular wall–derived endothelial colony–forming cells (ECFCs), would synergistically protect the developing retinal vasculature in a mouse model of ROP, called oxygen-induced retinopathy (OIR). CD34 + cells alone, ECFCs alone, or the combination thereof were injected intravitreally at either P5 or P12 and pups were euthanized at P17. Retinas from OIR mice injected with ECFCs or the combined treatment revealed formation of the deep vascular plexus (DVP) while still in hyperoxia, with normal-appearing connections between the superficial vascular plexus (SVP) and the DVP. In addition, the combination of cells completely prevented aberrant retinal neovascularization and was more effective anatomically and functionally at rescuing the ischemia phenotype than either cell type alone. We show that the beneficial effects of the cell combination are the result of their ability to orchestrate an acceleration of vascular development and more rapid ensheathment of pericytes on the developing vessels. Lastly, our proteomic and transcriptomic data sets reveal pathways altered by the dual cell therapy, including many involved in neuroretinal maintenance, and principal component analysis (PCA) showed that cell therapy restored OIR retinas to a state that was closely associated with age-matched normal retinas. Together, these data herein support the use of dual cell therapy as a promising preventive treatment for the development of ROP in premature infants.

17 July 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
CDCosta Dalis
Costa Dalis
FMFikir M. Mesfin
Fikir M. Mesfin
KMKrishna Manohar
Krishna Manohar
JLJianyun Liu
Jianyun Liu
CSChris Shelley
Chris Shelley
TMTroy A. Markel
Troy A. Markel
Gastrointestinal (GI) diseases have a high prevalence throughout the United States. Screening and diagnostic modalities are often expensive and invasive, and therefore, people do not utilize them effectively. Lack of proper screening and diagnostic assessment may lead to delays in diagnosis, more advanced disease at the time of diagnosis, and higher morbidity and mortality rates. Research on the intestinal microbiome has demonstrated that dysbiosis, or unfavorable alteration of organismal composition, precedes the onset of clinical symptoms for various GI diseases. GI disease diagnostic research has led to a shift towards non-invasive methods for GI screening, including chemical-detection tests that measure changes in volatile organic compounds (VOCs), which are the byproducts of bacterial metabolism that result in the distinct smell of stool. Many of these tools are expensive, immobile benchtop instruments that require highly trained individuals to interpret the results. These attributes make them difficult to implement in clinical settings. Alternatively, electronic noses (E-noses) are relatively cheaper, handheld devices that utilize multi-sensor arrays and pattern recognition technology to analyze VOCs. The purpose of this review is to (1) highlight how dysbiosis impacts intestinal diseases and how VOC metabolites can be utilized to detect alterations in the microbiome, (2) summarize the available VOC analytical platforms that can be used to detect aberrancies in intestinal health, (3) define the current technological advancements and limitations of E-nose technology, and finally, (4) review the literature surrounding several intestinal diseases in which headspace VOCs can be used to detect or predict disease.

24 February 2021 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
BHBrian D. Hosfield
Brian D. Hosfield
NDNatalie A. Drucker
Natalie A. Drucker
APAnthony R. Pecoraro
Anthony R. Pecoraro
CSChris Shelley
Chris Shelley
HLHongge Li
Hongge Li
TMTroy A. Markel
Troy A. Markel

20 November 2024 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
PCPaul J Childress
Paul J Childress
JNJeffery J Nielsen
Jeffery J Nielsen
TBThomas B Bemenderfer
Thomas B Bemenderfer
UDUshashi Dadwal
Ushashi Dadwal
NCNabarun Chakraborty
Nabarun Chakraborty
Melissa Ann KacenaMelissa Ann Kacena
Melissa Ann Kacena
Achieving bone union remains a significant clinical dilemma. The use of osteoinductive agents, specifically bone morphogenetic proteins (BMPs), has gained wide attention. However, multiple side effects, including increased incidence of cancer, have renewed interest in investigating alternatives that provide safer, yet effective bone regeneration. Here we demonstrate the robust bone healing capabilities of the main megakaryocyte (MK) growth factor, thrombopoietin (TPO), and second-generation TPO agents using multiple animal models, including mice, rats, and pigs. This bone healing activity is shown in two fracture models (critical-sized defect [CSD] and closed fracture) and with local or systemic administration. Our transcriptomic analyses, cellular studies, and protein arrays demonstrate that TPO enhances multiple cellular processes important to fracture healing, particularly angiogenesis, which is required for bone union. Finally, the therapeutic potential of thrombopoietic agents is high since they are used in the clinic for other indications (eg, thrombocytopenia) with established safety profiles and act upon a narrowly defined population of cells.